MedPath

To Study Effect of the Combination of Midodrine and Tolvaptan (drug) Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis (Liver Disease).

Not Applicable
Conditions
Health Condition 1: K769- Liver disease, unspecified
Registration Number
CTRI/2021/09/036265
Lead Sponsor
Institute of Liver and Biliary Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Child B/C cirrhosis

2) Hyponatremia( severe)

3) Written informed consent

4) Age-18-70 years

Exclusion Criteria

1.AKI(1.5mg/dl)

2.Sepsis

3.Underlyig CKD

4.High risk varices

5.Recent Bleed in 2 weeks

6.Acute Symptomatic hyponatremia

7.SIADH

8.Hypothyroidism

9.Severe cardiopulmonary disease

10.Cerebrovascular accident

11.Multiple strokes;

Pseudohyponatremia

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath